NCT07778316
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07778316
Title Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) (DeLLphi-315)
Acronym DeLLphi-315
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CHE | AUS

Facility Status City State Zip Country Details
University of Florida Health Cancer Center at Orlando Health RECRUITING Orlando Florida 32806 United States Details
Cancer and Hematology Centers of Western Michigan RECRUITING Grand Rapids Michigan 49503 United States Details
Oncology Hematology West PC RECRUITING Omaha Nebraska 68130 United States Details
Lyell McEwin Hospital RECRUITING Elizabeth Vale South Australia 5112 Australia Details
Beijing Chaoyang Hospital RECRUITING Beijing Beijing Municipality 100020 China Details
Beijing Cancer Hospital RECRUITING Beijing Beijing Municipality 100142 China Details
Shanghai Pulmonary Hospital RECRUITING Shanghai 200433 China Details
Tokyo Metropolitan Komagome Hospital RECRUITING Bunkyo-ku Tokyo 113-8677 Japan Details
Universitaetsspital Zuerich RECRUITING Zurich 8091 Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field